Non-inferiority Study of XM02 Filgrastim (Granix) and Filgrastim (Neupogen) in Combination With Plerixafor for Autologous Stem Cell Mobilization in Patients With Multiple Myeloma or Non-Hodgkin Lymphoma

Inclusion Criteria:

At least 18 years of age
Diagnosis of multiple myeloma or non-Hodgkin lymphoma
Eligible for autologous transplantation

Adequate bone marrow function as defined as:

White Blood Cell Count ≥ 3.0x109/L
Absolute Neutrophil Count ≥ 1.5x109/L
Platelet Count ≥ 100x109/L
Able to understand and willing to sign an IRB-approved informed consent document

Surgically or biologically sterile or willing to practice acceptable birth control, as follows:

Women of childbearing potential must have a negative serum or urine pregnancy test within 7 days of Day 1 of study treatment. Women of childbearing potential must agree to abstain from sexual activity or use a medically approved contraceptive measure/regimen during and for 3 months after the treatment period. Acceptable methods of birth control include: barriers (condoms), oral contraceptive, intrauterine device (IUD), transdermal/implanted or injected contraceptives, and abstinence
Males must agree to abstain from sexual activity or agree to utilize a medically approved contraception method during and for 3 months after the treatment period. Acceptable methods of birth control include: barriers (condoms), oral contraceptive, intrauterine device (IUD), transdermal/implanted or injected contraceptives, and abstinence

Exclusion Criteria:

Previous autologous stem cell collection
Known hypersensitivity to filgrastim, plerixafor, or E. coli derived products
Pregnant or breastfeeding